Table 2.

Industry capsaicinoid pipeline (low-dose capsaicin studies not included).

Compound	Company	Study population	Current status
Agonist
Aldea, ALGRX-4975 [ClinicalTrials.gov identifiers: NCT00130949, NCT00130962, NCT00132392, NCT00133133, NCT00146198, NCT00672568, NCT00681356, NCT00683267, NCT00583180]	Anesiva	Nine studies completed, three for knee replacement, one tennis elbow, two postoperative pain, one for hip replacement, one for shoulder arthroscopy, one for Morton’s neuroma and one for intraoperative wound instillation	No active studies posted
Civamide, WN 1001 [ClinicalTrials.gov identifiers: NCT00033839, NCT00069082, NCT00077935, NCT00758433, NCT00802217, NCT00995306, NCT00845923, NCT01341548]	Winston Labs	Intranasal, patch, cream and oral. Eight studies in total, three in cluster headache, two in osteoarthritis, one in post-herpetic neuralgia, two phase I	Current study, nasal administration for cluster headaches; not yet enrolling
Qutenza, NGX 4010 See the text, vide supra.	Neurogesx (purchased by Acorda in 2013)	See Table 1	See Table 1